HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million seed financing led by TMC Venture Fund and CE-Ventures, the corporate venture capital platform of Crescent Enterprises, with participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors..

休斯顿--（商业新闻短讯）--生物技术公司CrossBridge Bio是一家开创双有效载荷抗体-药物偶联物（ADC）作为靶向癌症治疗的生物技术公司，今天宣布关闭由TMC风险基金和CE Ventures牵头的1000万美元种子融资，CE Ventures是新月企业的企业风险投资平台，门户创新，亚历山大风险投资，林登湖实验室和一些种子前投资者参与。

Based on breakthrough research from Dr. Kyoji Tsuchikama and Dr. Zhiqiang An of UTHealth Houston, CrossBridge Bio’s dual-payload ADC platform combines both established and novel antibodies with various payload mechanisms of action, to develop a suite of ADC programs designed to offer distinct molecular properties, pharmacological actions, including payload synergy, and safety profiles for a range of cancer indications.

基于UTHealth Houston的Kyoji Tsuchikama博士和An Zhiqiang博士的突破性研究，CrossBridge Bio的双有效载荷ADC平台将已建立和新型抗体与各种有效载荷作用机制相结合，开发了一套ADC程序，旨在为一系列癌症适应症提供独特的分子特性，药理作用，包括有效载荷协同作用和安全性。

The seed capital will fund the development of the company’s lead program, CBB-120, a potential best-in-class TROP-2 dual-payload ADC for the treatment of solid tumors, and accelerate the expansion of its pipeline of novel ADC programs. Additionally, funds will be used to further derisk the company’s proprietary linker technology with dual-payload applications, a critical component of its ADC platform, to improve the safety and efficacy profiles of its current and future drug candidates..

种子资本将资助该公司的领先项目CBB-120的开发，CBB-120是一种潜在的一流TROP-2双有效载荷ADC，用于治疗实体瘤，并加速其新型ADC项目的扩展。此外，资金将用于进一步挑战该公司专有的双有效载荷应用链接器技术，这是其ADC平台的关键组成部分，以提高其当前和未来候选药物的安全性和有效性。

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” said Michael Torres, Ph.D., CEO of CrossBridge Bio. “Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments.

CrossBridge Bio首席执行官迈克尔·托雷斯（MichaelTorres）博士说：“我们很高兴得到这些经验丰富的投资者的支持，他们分享了我们为有需要的患者带来变革性癌症治疗的愿景。我们的双有效载荷ADC技术旨在使用高度稳定的接头提供协同治疗效果，确保有效载荷仅在靶向癌细胞内释放，从而最大程度地提高其治疗效果，同时最大程度地减少与非预期组织摄取相关的责任，正如当今许多癌症治疗所见。

With these funds, the seasoned team we have built at CrossBridge will advance CBB-120, the first development candidate in our portfolio, into preclinical non-GLP toxicology studies and lay the groundwork for its future clinical development.”.

有了这些资金，我们在CrossBridge建立的经验丰富的团队将推动我们投资组合中的第一个开发候选人CBB-120进入临床前非GLP毒理学研究，并为其未来的临床开发奠定基础。”

As part of this financing, both William McKeon, President and CEO of the Texas Medical Center (TMC), and Damir Illich, Ph.D. Manager, Life Sciences of CE-Ventures, will join CrossBridge Bio’s board of directors, bringing extensive experience in healthcare and life sciences to support the company’s strategic growth..

作为此次融资的一部分，德克萨斯州医疗中心（TMC）总裁兼首席执行官威廉·麦基恩（William McKeon）和CE Ventures生命科学博士经理达米尔·伊利奇（Damir Illich）将加入CrossBridge Bio的董事会，为公司的战略增长带来医疗保健和生命科学方面的丰富经验。

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” said Mr. McKeon. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”.

“我们很自豪地支持CrossBridge Bio开发下一代癌症疗法的使命，”McKeon先生说。“他们的双有效载荷ADC旨在以更高的稳定性，精确度和控制力在癌细胞内提供靶向药物释放。这些突破性进展有可能改变全球患者的生活，我们期待着帮助推动他们的发展。”

“CrossBridge Bio’s innovative platform and ambitious pipeline have positioned the company as a new leader in the ADC drug discovery and development arena,” said Dr. Illich. “We are excited to support their efforts to translate their platform innovations into therapies that meaningfully impact patients’ lives, starting with CBB-120.”.

Illich博士说：“CrossBridge Bio的创新平台和雄心勃勃的管道使该公司成为ADC药物发现和开发领域的新领导者。”。“从CBB-120开始，我们很高兴支持他们将平台创新转化为对患者生活产生重大影响的疗法。”

About CrossBridge Bio, Inc.

关于CrossBridge Bio，Inc。

CrossBridge Bio is pioneering an approach to deliver the next generation of stable antibody-drug conjugates (ADC) therapeutics that carry dual payloads as targeted treatments for a range of challenging cancers. Leveraging technology from the labs of Dr. Kyoji Tsuchikama and Dr. Zhiqiang An from UTHealth Houston, including a proprietary linker that offers greater stability and the ability to attach multiple payloads, the company aims to improve therapeutic indices and tackle tumor heterogeneity and resistance.

CrossBridge Bio开创了一种提供下一代稳定抗体-药物偶联物（ADC）疗法的方法，该疗法具有双重有效载荷，可作为一系列具有挑战性的癌症的靶向治疗方法。该公司利用来自UTHealth Houston的Kyoji Tsuchikama博士和An Zhiqiang博士实验室的技术，包括提供更高稳定性和连接多个有效载荷能力的专有连接器，旨在改善治疗指数并解决肿瘤异质性和耐药性。

CrossBridge Bio is advancing a portfolio of dual-payload ADC programs for solid tumor cancers, led by CBB-120, a potential best-in-class TROP2 ADC for certain breast cancers and other TROP2-positive cancers where the dual payloads will be most effective. CrossBridge Bio was formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program and is headquartered in Houston, TX.

CrossBridge Bio正在推进一系列针对实体瘤癌症的双有效载荷ADC计划，由CBB-120领导，CBB-120是一种潜在的同类最佳TROP2 ADC，用于某些乳腺癌和其他TROP2阳性癌症，其中双有效载荷将是最有效的。CrossBridge Bio成立于TMC创新癌症治疗加速器计划期间，总部位于德克萨斯州休斯顿。

Learn more at www.crossbridgebio.com..

更多信息，请访问www.crossbridgebio.com。